Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 Jul;76(1):233–240. doi: 10.1172/JCI111952

Inhibition and subsequent enhancement of platelet responsiveness by prostacyclin in the rabbit. Relationship to platelet adenosine 3',5'-cyclic monophosphate.

M Vanderwel, R J Haslam
PMCID: PMC423753  PMID: 2991338

Abstract

Methods were developed for measuring changes in platelet sensitivity to a release-inducing stimulus and in platelet cyclic AMP in fresh whole blood samples from rabbits. These techniques permitted detection of the effects of exogenous and endogenous prostacyclin on circulating platelets. In these methods, rabbit platelets were labeled in vitro by incubation with [14C]serotonin and [3H]adenine and then transfused into other rabbits. Release of platelet [14C]serotonin by a standard dose of synthetic platelet-activating factor (40 pmol/ml) and the platelet cyclic [3H]AMP levels were then measured in citrated blood from the conscious animals within 2 min of arterial puncture. Bolus intravenous injections of prostacyclin (1-10 nmol/kg) caused concentration-dependent increases in platelet cyclic AMP after 2 min, which decreased approximately 75% by 5 min, and disappeared after 30 min. Significant inhibition of the platelet release reaction was detected 2 min but not 5 min after injection of 10 nmol of prostacyclin per kilogram. With lower doses, significant enhancement of the release of [14C]serotonin was observed after 5 min. Similar changes in platelet responsiveness and cyclic [3H]AMP were observed after release of endogenous prostacyclin by intravenous injection of angiotensin II (5 nmol/kg); inhibition of the release of [14C]serotonin after 2 min was followed by potentiation after 5 min, though platelet cyclic [3H]AMP remained above control values. In these experiments, the time course of the changes in platelet cyclic [3H]AMP correlated closely with values for blood prostacyclin obtained previously (Haslam, R.J., and M.D. McClenaghan, 1981, Nature [Lond.]., 292:364-366). Prostacyclin also had a biphasic effect on the release of [14C]serotonin when added to citrated blood in vitro, though both the increase in sensitivity to platelet-activating factor and the return of platelet cyclic [3H]AMP towards control values took place more slowly. At all times, addition of platelet-activating factor decreased platelet cyclic [3H]AMP towards but not below the control level observed in the absence of prostacyclin. Our results indicate that although transient increases in platelet cyclic AMP cause an immediate decrease in platelet responsiveness in vivo or in vitro, a period of enhanced platelet sensitivity follows as platelet cyclic AMP falls.

Full text

PDF
233

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASTER R. H., JANDL J. H. PLATELET SEQUESTRATION IN MAN. I. METHODS. J Clin Invest. 1964 May;43:843–855. doi: 10.1172/JCI104970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aiken J. W., Shebuski R. J., Miller O. V., Gorman R. R. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. J Pharmacol Exp Ther. 1981 Nov;219(2):299–308. [PubMed] [Google Scholar]
  3. Anderson G. M., Young J. G., Cohen D. J., Schlicht K. R., Patel N. Liquid-chromatographic determination of serotonin and tryptophan in whole blood and plasma. Clin Chem. 1981 May;27(5):775–776. [PubMed] [Google Scholar]
  4. BRECHER G., CRONKITE E. P. Morphology and enumeration of human blood platelets. J Appl Physiol. 1950 Dec;3(6):365–377. doi: 10.1152/jappl.1950.3.6.365. [DOI] [PubMed] [Google Scholar]
  5. Blackwell G. J., Radomski M., Vargas J. R., Moncada S. Prostacyclin prolongs viability of washed human platelets. Biochim Biophys Acta. 1982 Sep 17;718(1):60–65. doi: 10.1016/0304-4165(82)90009-5. [DOI] [PubMed] [Google Scholar]
  6. Blair I. A., Barrow S. E., Waddell K. A., Lewis P. J., Dollery C. T. Prostacyclin is not a circulating hormone in man. Prostaglandins. 1982 Apr;23(4):579–589. doi: 10.1016/0090-6980(82)90118-6. [DOI] [PubMed] [Google Scholar]
  7. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  8. Cardinal D. C., Flower R. J. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods. 1980 Feb;3(2):135–158. doi: 10.1016/0160-5402(80)90024-8. [DOI] [PubMed] [Google Scholar]
  9. Christ-Hazelhof E., Nugteren D. H. Prostacyclin is not a circulating hormone. Prostaglandins. 1981 Nov;22(5):739–746. doi: 10.1016/0090-6980(81)90213-6. [DOI] [PubMed] [Google Scholar]
  10. Czer G. T., Moser K. M. Dissociation between hemodynamic and platelet antiaggregant effects of prostacyclin in dogs determined with a rapid platelet isolation technique. J Lab Clin Med. 1983 Jul;102(1):133–139. [PubMed] [Google Scholar]
  11. Data J. L., Molony B. A., Meinzinger M. M., Gorman R. R. Intravenous infusion of prostacyclin sodium in man: clinical effects and influence on platelet adenosine diphosphate sensitivity and adenosine 3':5'-cyclic monophosphate levels. Circulation. 1981 Jul;64(1):4–12. doi: 10.1161/01.cir.64.1.4. [DOI] [PubMed] [Google Scholar]
  12. Deckmyn H., Van Houtte E., Verstraete M., Vermylen J. Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom. Biochem Pharmacol. 1983 Sep 15;32(18):2757–2762. doi: 10.1016/0006-2952(83)90088-6. [DOI] [PubMed] [Google Scholar]
  13. Dembinska-Kiec A., Zmuda A., Grodzinska L., Bieron K., Basista M., Kedzior A., Kostka-Trabka E., Telesz E., Zelazny T. Increased platelet activity after termination of prostacyclin infusion into man. Prostaglandins. 1981 May;21(5):827–832. doi: 10.1016/0090-6980(81)90239-2. [DOI] [PubMed] [Google Scholar]
  14. Dusting G. J. Angiotensin-induced release of a prostacyclin-like substance from the lungs. J Cardiovasc Pharmacol. 1981 Jan-Feb;3(1):197–206. doi: 10.1097/00005344-198101000-00018. [DOI] [PubMed] [Google Scholar]
  15. Enyedi A., Faragó A., Sarkadi B., Szász I., Gárdos G. Cyclic AMP-dependent protein kinase stimulates the formation of polyphosphoinositides in the plasma membranes of different blood cells. FEBS Lett. 1983 Sep 5;161(1):158–162. doi: 10.1016/0014-5793(83)80751-0. [DOI] [PubMed] [Google Scholar]
  16. Fox J. E., Say A. K., Haslam R. J. Subcellular distribution of the different platelet proteins phosphorylated on exposure of intact platelets to ionophore A23187 or to prostaglandin E1. Possible role of a membrane phosphopolypeptide in the regulation of calcium-ion transport. Biochem J. 1979 Dec 15;184(3):651–661. doi: 10.1042/bj1840651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gorman R. R., Bunting S., Miller O. V. Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins. 1977 Mar;13(3):377–388. doi: 10.1016/0090-6980(77)90018-1. [DOI] [PubMed] [Google Scholar]
  18. Gryglewski R. J., Korbut R., Ocetkiewicz A. Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature. 1978 Jun 29;273(5665):765–767. doi: 10.1038/273765a0. [DOI] [PubMed] [Google Scholar]
  19. Haslam R. J., Davidson M. M., Davies T., Lynham J. A., McClenaghan M. D. Regulation of blood platelet function by cyclic nucleotides. Adv Cyclic Nucleotide Res. 1978;9:533–552. [PubMed] [Google Scholar]
  20. Haslam R. J., McClenaghan M. D. Measurement of circulating prostacyclin. Nature. 1981 Jul 23;292(5821):364–366. doi: 10.1038/292364a0. [DOI] [PubMed] [Google Scholar]
  21. Haslam R. J., Vanderwel M. Inhibition of platelet adenylate cyclase by 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor). J Biol Chem. 1982 Jun 25;257(12):6879–6885. [PubMed] [Google Scholar]
  22. Ingerman-Wojenski C. M., Smith J. B., Silver M. J. Difficulty in detecting inhibition of platelet aggregation by the impedance method. Thromb Res. 1982 Nov 1;28(3):427–432. doi: 10.1016/0049-3848(82)90124-4. [DOI] [PubMed] [Google Scholar]
  23. Ingerman C. M., Smith J. B., Silver M. J. Direct measurement of platelet secretion in whole blood. Thromb Res. 1979;16(3-4):335–344. doi: 10.1016/0049-3848(79)90081-1. [DOI] [PubMed] [Google Scholar]
  24. Jørgensen K. A., Dyerberg J., Stoffersen E. A biphasic effect of prostacyclin (PGI2) on platelet aggregation. Thromb Res. 1980 Sep 15;19(6):877–881. doi: 10.1016/0049-3848(80)90015-8. [DOI] [PubMed] [Google Scholar]
  25. Käser-Glanzmann R., Jakäbovä M., George J. N., Lüscher E. F. Stimulation of calcium uptake in platelet membrane vesicles by adenosine 3',5'-cyclic monophosphate and protein kinase. Biochim Biophys Acta. 1977 May 2;466(3):429–440. doi: 10.1016/0005-2736(77)90336-4. [DOI] [PubMed] [Google Scholar]
  26. Moncada S., Gryglewski R., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976 Oct 21;263(5579):663–665. doi: 10.1038/263663a0. [DOI] [PubMed] [Google Scholar]
  27. Moncada S., Korbut R., Bunting S., Vane J. R. Prostacyclin is a circulating hormone. Nature. 1978 Jun 29;273(5665):767–768. doi: 10.1038/273767a0. [DOI] [PubMed] [Google Scholar]
  28. Moncada S., Vane J. R. The role of prostacyclin in vascular tissue. Fed Proc. 1979 Jan;38(1):66–71. [PubMed] [Google Scholar]
  29. Needleman P., Wyche A., Raz A. Platelet and blood vessel arachidonate metabolism and interactions. J Clin Invest. 1979 Feb;63(2):345–349. doi: 10.1172/JCI109309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Perper R. J., Zee T. W., Mickelson M. M. Purification of lymphocytes and platelets by gradient centrifugation. J Lab Clin Med. 1968 Nov;72(5):842–848. [PubMed] [Google Scholar]
  31. Reele S. B., Miller O. V., Spillers C., Gorman R. R. The effects of continuous infusions of prostacyclin-Na (epoprostenol-sodium) on platelet counts, ADP-induced aggregation, and cyclic AMP levels in normal volunteers. Prostaglandins. 1983 Aug;26(2):287–302. doi: 10.1016/0090-6980(83)90096-5. [DOI] [PubMed] [Google Scholar]
  32. Sinzinger H., Horsch A. K., Silberbauer K. The behaviour of various platelet function tests during long-term prostacyclin infusion in patients with peripheral vascular disease. Thromb Haemost. 1983 Dec 30;50(4):885–887. [PubMed] [Google Scholar]
  33. Sinzinger H., Silberbauer K., Horsch A. K., Gall A. Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease--a rebound phenomenon? Prostaglandins. 1981 Jan;21(1):49–51. doi: 10.1016/0090-6980(81)90195-7. [DOI] [PubMed] [Google Scholar]
  34. Smith J. B., Ogletree M. L., Lefer A. M., Nicolaou J. C. Antibodies which antagonise the effects of prostacyclin. Nature. 1978 Jul 6;274(5666):64–65. doi: 10.1038/274064a0. [DOI] [PubMed] [Google Scholar]
  35. Splawinski J., Gwozdz B., Ziembicki W., Ziajor M., Splawinska B. Anti-aggregatory activity of PGI2 in whole blood measured by platelet counter. Thromb Res. 1984 Apr 15;34(2):93–102. doi: 10.1016/0049-3848(84)90065-3. [DOI] [PubMed] [Google Scholar]
  36. Steer M. L., MacIntyre D. E., Levine L., Salzman E. W. Is prostacyclin a physiologically important circulating anti-platelet agent? Nature. 1980 Jan 10;283(5743):194–195. doi: 10.1038/283194a0. [DOI] [PubMed] [Google Scholar]
  37. Swies J., Radomski M., Gryglewski R. J. Angiotensin-induced release of prostacyclin (PGI2) into circulation of anaesthetized cats. Pharmacol Res Commun. 1979 Sep;11(8):649–655. doi: 10.1016/s0031-6989(79)80055-7. [DOI] [PubMed] [Google Scholar]
  38. Tateson J. E., Moncada S., Vane J. R. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins. 1977 Mar;13(3):389–397. doi: 10.1016/0090-6980(77)90019-3. [DOI] [PubMed] [Google Scholar]
  39. Ubatuba F. B., Moncada S., Vane J. R. The effect of prostacyclin (PGT2) on platelet behaviour. Thrombus formation in vivo and bleeding time. Thromb Haemost. 1979 Apr 23;41(2):425–435. [PubMed] [Google Scholar]
  40. Vermylen J., Chamone D. A., Verstraete M. Stimulation of prostacyclin release from vessel wall by Bay g 6575, an antithrombotic compound. Lancet. 1979 Mar 10;1(8115):518–520. doi: 10.1016/s0140-6736(79)90944-9. [DOI] [PubMed] [Google Scholar]
  41. Whittle B. J., Moncada S., Vane J. R. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins. 1978 Sep;16(3):373–388. doi: 10.1016/0090-6980(78)90216-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES